NLS Agreement

Scandinavian Biopharma has entered into a distribution agreement with Bio Products Laboratory Limited (BPL), a manufacturer of plasma-derived protein therapies, for their factor X deficiency product Coagadex. Coagadex is a treatment for factor X deficiency bleeding disorder in Europe. Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in […]

MC2 Therapeutics has announced a collaboration agreement with EPI Health on the commercialization of WYNZORA Cream in the US. WYNZORA Cream was approved by the U.S. Food and Drug Administration (FDA) on July 20th, 2020 for the topical treatment of plaque psoriasis in adults, 18 years of age or older. “The upcoming launch of WYNZORA […]

The collaboration, announced in August, is one of the broadest partnerships within the U.S. biosimilar industry to date to accelerate improved patient access for high quality biosimilar medicines in the U.S. biosimilar industry. Alvotech and Teva Pharmaceutical Industries have entered into an exclusive strategic partnership for the commercialization in the U.S. of five biosimilar product […]

Lytix Biopharma licenses its lead candidate LTX-315, an oncolytic peptide based immunotherapy, to Verrica Pharmaceuticals, for the treatment of dermatologic oncology indications. “With aggregate payments of more than $110M” Lytix is entitled to receive an up-front payment, contingent regulatory milestones based on achievement of specified development goals, and sales milestones, with aggregate payments of more […]

AstraZeneca has entered into a new global development and commercialization agreement with Daiichi Sankyo Company, for DS-1062, Daiichi Sankyo’s trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential new medicine for the treatment of multiple tumour types. DS-1062 is currently in development for the treatment of multiple tumours that commonly express the cell-surface […]

BioInvent International announced on July 1st that it has further extended the research term under its cancer immunotherapy research collaboration and license agreement with Pfizer until the end of 2020. In December 2016, the companies entered into the agreement for the development and commercialization of antibodies targeting tumor-associated myeloid cells discovered using BioInvent’s F.I.R.S.TTM drug […]